ReposiTrak's fiscal fourth quarter delivered the pattern investors have seen all year, only sharper. Profits rose while the top line faded. Earnings came in at $0.11 per share, up 22.2% from $0.09 a year earlier, but revenue fell 3.2% to $5.58 million. That is the first year-over-year revenue decline in four quarters. No consensus estimate was available, so there is no beat or miss to judge. The more important comparison is internal: quarterly revenue growth slid from +10% in Q1 to +7%, then flat, and now negative. That is the central tension. A company that framed itself around 10-20% recurring revenue growth at the start of the fiscal year finished with 3% full-year growth to $23.3 million. Management is now asking investors to look to 2027 for the reacceleration.
The quality of the earnings growth deserves scrutiny. Quarterly operating expense fell 11% to $3.7 million, which lifted operating income 19% to $1.9 million. For the full year, operating income rose 26% to $7.8 million and operating margin expanded to 33.7% from 27.5%. Much of that leverage came from the cost line rather than from demand:
- **Lower amortization:** Depreciation and amortization roughly halved to $648,000 as older capitalized software rolled off.
- **Newly capitalized software:** The company capitalized about $1.0 million of new software development. The call acknowledged this flatters the cost-of-services line.
- **Interest income:** Below the operating line, interest income of $1.5 million supplied a meaningful slice of the $9.5 million in pretax income.
There was a real headwind as well. The tax provision jumped to roughly $1.9 million from $676,000 as net operating losses run off, a drag of about 6.5 cents on full-year EPS. Diluted EPS still rose to $0.39 from $0.35, which shows the underlying profitability is real. It is simply being produced by a business that is not currently growing.
The balance sheet and cash flow add further nuance:
- **Operating cash flow:** $8.2 million, essentially flat with the prior year.
- **Cash:** $27.3 million, down from $28.6 million a year ago despite a sequential uptick from Q3.
- **Bad debt expense:** Rose to $950,000 from $600,000.
- **Receivables:** The cash flow statement shows $2.3 million of common stock received in settlement of receivables, a non-cash item that inflates reported earnings relative to cash collected.
- **Deferred revenue:** Climbed to $4.5 million from $3.2 million, a modestly encouraging signal on forward billings.
The call pivoted hard toward new growth drivers. The biggest is Touchless Merchandising with SPAR Group. It pairs ReposiTrak's real-time inventory detection with SPAR's in-store field force, and it moved from a single-prospect concept last quarter to a launched product with several contracts signed and executing. Management expects a little revenue next quarter and called the offering a "very significant" contributor in 2027. ReposiTrak is also financially tied to the bet. It extended SPAR a $4.0 million credit facility, with a $3 million note receivable on the books, and acquired about $2.4 million of SPAR stock. It now believes it is SPAR's largest shareholder.
That alignment cuts both ways. It deepens commitment to the partnership, but it also concentrates capital in a partner whose integration management itself called non-trivial. It diverts executive attention as well.
Traceability remains the other pillar. Management said FDA staff signaled no appetite for delaying the July 2028 Rule 204 deadline, and cited more than 160 food recalls year to date. Yet bears have legitimate ammunition here. The onboarding ramp promised for summer and early fall has again failed to show up in revenue, and the expected inflection has now shifted to year-end and 2027.
Macro pressure compounds the risk. Elevated diesel costs and a Kroger-led grocery price war are making customers cautious. No formal guidance was issued. Despite this, management's tone was the most confident of the year, saying it was "very, very confident about the next few years." That confidence rests on initiatives that have not yet produced revenue, which is why the call's optimism and the reported trajectory point in different directions.
The market setup offers limited but telling context. Shares opened at $9.27 after the May report, just below the current 200-day moving average of $9.38. That suggests the stock has spent recent months trading around its longer-term trend rather than rewarding the margin story. Notably, the company repurchased 143,904 shares during the fiscal year at an average of $12.50, well above where the stock traded after the prior report. The capital-return framework is unchanged:
- Roughly half of operating cash flow returned to shareholders.
- A $0.02 quarterly dividend.
- Full redemption of the remaining ~$1.7 million of preferred stock by December 2026.
The bottom line is that ReposiTrak remains a highly profitable, debt-free, cash-generative platform, but its fiscal 2026 earnings growth was built on cost discipline, amortization roll-off and interest income rather than customer demand. Revenue has decelerated every quarter and turned negative. The investment case now rests squarely on two timelines that keep moving: SPAR-driven Touchless Merchandising revenue and a traceability surge ahead of the 2028 FDA deadline. Until either shows up on the top line, the earnings growth is more a testament to efficiency than evidence of renewed growth.